What is it about?
The presence of a sloble target in immunogenicity testing makes the determination of the presence of ADAs very challenging. Soluble target can mask the epitopes of the reagents, resulting in false negative readout, or produce a false positive signal (multimers). In the case of pre treatment (binding the same soluble target, but at a different epitope comared to the administered drug), the determination of ADA can become even more challenging.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
We could demonstrate that a isoelectric target depletion (ITaD) could significantly reduce the concentration of soluble target without the use of target specific reagents.
Perspectives
Writing this article was a lot of fun for me from many points of view. Of course, dealing with the data holistically, but also the discussions I had with my colleagues. We have tried to keep the article in a kind of scientific "story". Step by step, the path we have taken to develop the assay...
Gregor Jordan
Roche Diagnostics GmbH
Read the Original
This page is a summary of: Novel isoelectric target depletion (ITaD) protocol reduces the need for specific reagents for immunogenicity testing, Bioanalysis, June 2022, Future Science,
DOI: 10.4155/bio-2022-0060.
You can read the full text:
Contributors
The following have contributed to this page
